Posted by Michael Wonder on 17 Jan 2025
Innovent receives NMPA breakthrough therapy designation for IBI343 (anti-CLDN18.2 ADC) as monotherapy for advanced pancreatic cancer
16 January 2025 - Innovent Biologics announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted breakthrough therapy designation for IBI343, a potentially best-in-class TOPO1i anti-CLDN18.2 antibody drug conjugate, as monotherapy for the treatment of CLDN18.2 positive advanced pancreatic ductal adenocarcinoma patients who have progressed after at least one line of prior systematic treatment.
